推动AML精准诊疗规范——吉瑞替尼《临床应用指导原则》发布,临床应用指导原则,吉瑞,白血病,替尼,肿瘤,治疗 ...

圣地亚哥--(BUSINESS WIRE)--(美国商业资讯)-- 一项开创性的研究 1 （对Pre-MEASURE研究 2 的DNA样本进行测序）强烈表明，在首次完全缓解 (CR) 的急性髓性白血病 (AML) 成人受试者的血液中检测的残留FLT3内部串联重复 (ITD) 突变与同种异体造血细胞移植（HCT）后较差的结果 ...

针对FLT3突变AML患者复发率高的问题，英国研究团队在NCRI AML19试验中开展DA+GO+米哚妥林联合治疗研究。结果显示91%总体缓解率 ...

本研究针对急性髓系白血病(AML)中TP53、FLT3、HLA-B和MUC4突变导致的 Venetoclax 耐药难题，开发了LY3009120(pan-RAF)+Sapanisertib(mTOR)(LS)和 ...

VANFLYTA is the first and only FLT3 inhibitor to be approved by the FDA specifically for FLT3-ITD positive AML and across the three phases of treatment – induction, consolidation and maintenance in ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active ...

An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML ...

Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating ...

Daiichi Sankyo Co. Ltd.’s quizartinib met the primary endpoint of overall survival in the pivotal phase III Quantum-First study, which tested the addition of quizartinib to chemotherapy vs.